ACS Chemical Neuroscience Molecule Spotlight on Telcagepant (MK-0974)

被引：3
|
作者：
Hopkins, Corey R. [1 ,2 ]
机构：
[1] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Neurosci Drug Discovery, Nashville, TN 37232 USA
来源：
ACS CHEMICAL NEUROSCIENCE | 2011年 / 2卷 / 07期
关键词：
MIGRAINE; HEADACHE; EFFICACY;
D O I：
10.1021/cn200059f
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Telcagepant (MK-0974) is a novel calcitonin gene-related peptide (CGRP) receptor antagonise currently undergoing clinical trials for migraine (http://www.merck.com/research/pipeline/home.html). MK-0974 is currently being studied in phase III clinical trials.
引用
收藏
页码：334 / 335
页数：2
相关论文
共 50 条
  • [31] ACS Chemical Neuroscience Molecule Spotlight on ELND006: Another γ-Secretase Inhibitor Fails in the Clinic
    Hopkins, Corey R.
    ACS CHEMICAL NEUROSCIENCE, 2011, 2 (06): : 279 - 280
  • [32] Examining the binding properties of MK-0974: A CGRP receptor antagonist for the acute treatment of migraine
    Moore, Eric L.
    Burgey, Christopher S.
    Paone, Daniel V.
    Shaw, Anthony W.
    Tang, Yui S.
    Kane, Stefanie A.
    Salvatore, Christopher A.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2009, 602 (2-3) : 250 - 254
  • [33] MK-0974 -: Calcitonin gene-related peptide (CGRP) antagonist antimigraine agent
    Wang, Y.
    Serradell, N.
    Rosa, E.
    Bolos, J.
    DRUGS OF THE FUTURE, 2008, 33 (02) : 116 - 122
  • [34] Efficacy and tolerability of a novel, oral CGRP antagonist, MK-0974, in the acute treatment of migraine
    Assaid, C.
    Fan, X.
    Furtek, C.
    Ho, Tony
    Jones, C.
    Mannix, L.
    Rapoport, A.
    CEPHALALGIA, 2007, 27 (06) : 759 - 759
  • [35] Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine
    Ho, T. W.
    Mannix, L. K.
    Fan, X.
    Assaid, C.
    Furtek, C.
    Jones, C. J.
    Lines, C. R.
    Rapoport, A. M.
    NEUROLOGY, 2008, 70 (16) : 1304 - 1312
  • [36] The novel oral CGRP antagonist, MK-0974, exhibits similar pharmacokinetics during and between migraine attacks
    Agrawal, N.
    Blanchard, R.
    Boyle, J. E.
    de Hoon, J.
    de Lepeleire, I.
    Kane, S. A.
    Murphy, M. G.
    Palcza, J.
    Sinclair, Simon
    Willson, K.
    Xu, Y.
    CEPHALALGIA, 2007, 27 (06) : 738 - 738
  • [37] MK-0974, a novel oral CGRP antagonist, exhibits similar pharmacokinetics during and between migraine attacks
    Sinclair, S. R.
    Boyle, J. E.
    de Lepeleire, I.
    Kane, S. A.
    Blanchard, R.
    Willson, K.
    Xu, Y.
    Agrawal, N.
    Palcza, J.
    de Hoon, J.
    Murphy, M. G.
    HEADACHE, 2007, 47 (05): : 811 - 812
  • [38] MK-0974 oral CGRP antagonist inhibits capsaicin-induced increase in dermal microvascular blood flow
    Sinclair, S. R.
    Kane, S. A.
    Xiao, A.
    Willson, K.
    Xu, Y.
    Hickey, L.
    Palcza, J.
    de Lepeleire, I.
    Vanmolkot, F.
    de Hoon, J.
    Murphy, M. G.
    HEADACHE, 2007, 47 (05): : 811 - 811
  • [39] Inhibition of capsaicin-induced increase in dermal microvascular blood flow by the oral CGRP antagonist, MK-0974
    de Hoon, J.
    de Lepeleire, I.
    Hickey, L.
    Kane, S. A.
    Murphy, M. G.
    Palcza, J.
    Sinclair, Simon
    Vanmolkot, F.
    Willson, K.
    Xiao, A.
    Xu, Y.
    CEPHALALGIA, 2007, 27 (06) : 738 - 739
  • [40] Assessment of the effect of MK-0974, an oral CGRP receptor antagonist, on spontaneous ischemia in patients with stable cardiovascular disease
    Behm, M. O.
    Blanchard, R. L.
    Murphy, M. G.
    Chodakewitz, J. A.
    Palcza, J. S.
    Harris, D. E.
    Butterfield, K. L.
    Smith, W. B.
    Haynes, E. M.
    Sackner-Bernstein, J.
    Preston, R. A.
    Krucoff, M. W.
    HEADACHE, 2008, 48 : S39 - S39
12345